Phase II trial of regorafenib in patients with imatinib resistrant gastrointestinal stromal tumor
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms RESET for GIST
- 06 Jan 2018 Planned End Date changed from 30 Sep 2018 to 5 Dec 2018.
- 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2017 Planned End Date changed from 18 Jan 2017 to 30 Sep 2018.